๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Colorectal Cancer (CRC)
Clinical trial register · China

Colorectal Cancer (CRC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Nanchang 5 Beijing 4 Hangzhou 4 Shanghai 4 Guangzhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Nanchang5 Beijing4 Hangzhou4 Shanghai4 Guangzhou3
All 14 locations
Target enrolment
to

Colorectal Cancer (CRC) trials in China

25 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
NCT07624214Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase 1
198
Hangzhou
2026-07
Not yet open
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer
NCT07683403Colorectal Cancer (CRC)
Fudan University
Phase 1/2
138
Shanghai
2026-06-30
Recruiting
Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients
NCT07574502Colorectal Cancer (CRC)
Sir Run Run Shaw Hospital
Not applicable
190
Binzhou, Hangzhou
2026-06-14
Not yet open
AI-Integrated Emotional Granularity Training for Resilience and Quality of Life in Colorectal Cancer Survivors
NCT07611071Colorectal Cancer (CRC)
The Hong Kong Polytechnic University
Not applicable
54
Kunshan, Suzhou, Suzhu
2026-06-01
Recruiting
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
NCT07448142Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 2
50
Guangzhou
2026-03-15
Recruiting
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT07435038Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
120
Hangzhou
2026-01-29
Recruiting
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
NCT07106892Colorectal Cancer (CRC)
Shanghai Henlius Biotech
Phase 2
60
Beijing, Jinan
2025-09-15
Not yet open
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
NCT07059338HER2 Positive, Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 2
34
Guangzhou
2025-07-11
Active, closed
Neoadjuvant Therapy ๏ผˆNALIRIFOX๏ผ‰ for Locally Advanced Colon and Upper Rectal Cancer
NCT07020468Colorectal Cancer (CRC)
Affiliated Cancer Hospital of Shantou University Medical College
Phase 4
57
Shantou
2025-05-15
Recruiting
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
NCT06904677Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
400
Beijing
2025-05-01
Recruiting
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT06895031Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Guangzhou JOYO Pharma Co., Ltd
Phase 2
210
Beijing
2025-03-31
Not yet open
Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery
NCT06860685Colorectal Cancer (CRC)
Sichuan Cancer Hospital and Research Institute
Phase 1/2
292
Chengdu
2025-03-01
Recruiting
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
NCT06791512Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum
Jun Huang
Phase 3
166
Guangzhou
2025-01-18
Recruiting
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
NCT07035002Colorectal Cancer (CRC), Tumor Infiltrating Lymphocytes, PD-1
Ruijin Hospital
Phase 1
29
Shanghai
2024-12-31
Recruiting
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
NCT06718738Colorectal Cancer (CRC)
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1
9
Beijing
2024-12-15
Recruiting
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
NCT07562659ctDNA, Colorectal Cancer (CRC), Adjuvant Chemotherapy
Fudan University
Phase 2
80
Shanghai
2024-11-01
Recruiting
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NCT06751966Colorectal Cancer (CRC)
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NCT06751953Colorectal Cancer (CRC)
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
NCT07047560Colorectal Cancer (CRC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2024-09-01
Recruiting
Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751940Colorectal Cancer (CRC)
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751914Colorectal Cancer (CRC)
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413Cancer Diagnosis, Liver Cancer, Adult, Cancer Screening, Colorectal Cancer (CRC)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Nanchang, Shanghai, Hangzhou
2022-09-01
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
Genmab
Phase 1/2
350
2019-09-17
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/colorectal-cancer-crc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies listing the condition Colorectal Cancer (CRC).

How many Colorectal Cancer (CRC) trials are recruiting in China?

17 of the 25 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Colorectal Cancer (CRC)), 25 studies
PhaseStudiesRecruitingShare
Phase 27628%
Not applicable6524%
Phase 1/24116%
Phase 13212%
Observational228%
Phase 3218%
Phase 4104%

Most active sponsors

Lead sponsors with the most studies (Colorectal Cancer (CRC))
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Nanchang University44
Fudan University21
Sun Yat-sen University21
Affiliated Cancer Hospital of Shantou University Medical College10
Beijing Immunochina Medical Science & Technology Co., Ltd.11
Betta Pharmaceuticals Co., Ltd.11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Genmab10
Guangzhou JOYO Pharma Co., Ltd11
Jun Huang11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.